Everolimus denied as not FDA-approved for this use by Kaiser Permanente?

Kaiser Permanente's specific coverage criteria for everolimus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Kaiser Issues a "Not FDA-Approved" Denial for Everolimus — and How to Respond

Everolimus holds FDA approval for multiple distinct indications. A "not FDA-approved" denial from Kaiser is typically not a statement that the drug lacks any FDA approval — it most often means the specific use being requested (the particular indication, combination, or line of therapy) falls outside the approved labeling Kaiser has on file, or Kaiser's policy treats the specific requested use as off-label. In oncology, however, federal law creates important protections for off-label uses that are supported by recognized clinical compendia.

## The Federal Appeal Framework

Under ACA §2719, this type of denial is fully appealable through internal appeal and then independent external review (IRO). External review must be requested within four months of final internal denial. For urgent oncology or transplant cases, request expedited review immediately — the timeline compresses to 72 hours.

For self-funded ERISA plans, ERISA §503 requires written explanation of the denial criteria and a full-and-fair review.

## The Off-Label Compendia Protection

Federal law — specifically CMS coverage standards incorporated by reference into ACA plan requirements — mandates that plans cover cancer treatments listed in recognized clinical compendia even when they are used off-label relative to the FDA indication. The NCCN Drugs and Biologics Compendium is the most widely recognized. If the requested use of everolimus appears there, the plan's ability to deny solely on the basis of "not FDA-approved" is severely limited.

## Two Paths in Your Appeal

Path A — This is an FDA-approved use: Print the current FDA prescribing label from DailyMed. Identify the exact indication section matching this patient's diagnosis and stage. Attach it to the appeal with a letter from the treating physician explaining the match.

Path B — This is an off-label but compendia-supported use: Print the relevant NCCN Compendium entry. Confirm the specific indication, regimen, and category rating. Attach it with the prescriber's letter explaining clinical necessity.

## Documentation to Gather

• FDA prescribing label (DailyMed printout): Highlighting the indication that matches, or the indication most closely related to the requested use.
• NCCN Compendium or other recognized compendia printout: The relevant entry for the requested use.
• Diagnosis, pathology, and staging records: Confirming the patient meets the indication described in the FDA label or compendia.
• Prescriber's medical-necessity letter: Explicitly rebutting the not-FDA-approved characterization by identifying the applicable label section or compendia listing.

## Criteria-Mapping Structure

| Kaiser Policy Basis for "Not FDA-Approved" | Rebuttal Evidence | |---|---| | [Copy the specific policy language from the denial] | [FDA label section / NCCN Compendium entry / chart diagnosis match] |

## Practical Next Steps

1. Obtain the denial letter with the specific policy language and the indication Kaiser claims is not approved. 2. Compare that characterization against the current FDA prescribing label and NCCN Compendium. 3. Have the treating specialist write a rebuttal letter with the specific label or compendia citation. 4. File internally with all documentation attached. 5. If denied, escalate to independent external review — IRO reviewers must apply FDA labeling and federal compendia standards, not just Kaiser's internal coverage definitions.